Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells.
Human cell lines (the T-cell lines H9, Jurkat, and HUT102, the myeloid lines U937 and HL60, and the Raji B cell line) were infected with HIV-1. HIV-1 antigen could be detected by immunofluorescence analysis in more than 50% of T cells and myeloid cells 15 days after infection. Infection of Raji cells took more than 2-3 months. Studies of cell surface marker expression revealed remarkable changes after HIV-1 infection of Raji cells: expression of CR2 (C3d/EBV receptor, CD19, CD20, CD22, CD23, CD10, and surface IgM) were highly reduced, in the case of CR2 and membrane-IgM from 100 to 0%, whereas levels of CD37 and CD38 remained unaltered by HIV-1 infection. U937 cells showed a reduction of CD4 expression from 14 to 5% after HIV-1 infection; the CR3 expression slightly increased from 25 to 30%. In contrast, HLA-DR was only expressed (21%) after HIV-1 infection but not in uninfected U937 cells. Expression of HLA-DR could be detected also in HL60 cells (33%) after HIV-1 infection. In H9 cells, CD4 was reduced from 60 to 30% after HIV-1 infection, whereas HLA-DR and CD25/IL-2 receptor expression increased from 16 to 90% and from 0 to 50%, respectively. CD4 was reduced from 70 to 0% from Jurkat cells after HIV-1 infection, whereas expression of CR2 was only slightly diminished from 8 to 4%. Expression of CR1 and HLA-DR was slightly increased in these cells (1 to 3%).(ABSTRACT TRUNCATED AT 250 WORDS)
Larcher
C
C
Institut für Hygiene, Universität Innsbruck, Austria.
Schulz
T F
TF
Hofbauer
J
J
Hengster
P
P
Romani
N
N
Wachter
H
H
Dierich
M P
MP
D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000382:microbiology*; D015415:Biomarkers / Q000032:analysis*; D015704:CD4 Antigens / Q000096:biosynthesis; D002460:Cell Line; D003179:Complement C3b / Q000378:metabolism; D015933:Complement C3d / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D015488:HIV Antigens / Q000032:analysis; D015497:HIV-1 / Q000276:immunology / Q000502:physiology*; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute; D011951:Receptors, Complement / Q000096:biosynthesis*; D017463:Receptors, Complement 3b; D017464:Receptors, Complement 3d; D013601:T-Lymphocytes / Q000382:microbiology*; D014407:Tumor Cells, Cultured
D000944:Antigens, Differentiation, B-Lymphocyte; D015415:Biomarkers; D015704:CD4 Antigens; D015488:HIV Antigens; D006684:HLA-DR Antigens; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D017464:Receptors, Complement 3d; D003179:Complement C3b; D015933:Complement C3d